The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | The emerging roles of NGS and liquid biopsies in pancreatic cancer
Philip Philip, MD, PhD, FRCP, Wayne State University School of Medicine/Henry Ford Health, Detroit, MI, discusses the future of next-generation sequencing (NGS) for patients with pancreatic cancer. The detection of mutations such as BRCA, PALB2, and DDR defects enable clinicals to provide targeted therapies to patients. PARP inhibitors can target DDR defects, and immunotherapy can be given to patients with microsatellite stable (MSS) or tumor mutational burden (TMB) high pancreatic cancer. NGS can also benefit patients with KRAS-wild type tumors, where personalized therapies can be given. Liquid biopsies additionally have a growing role, where small samples sizes are not suitable for NGS. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
